A phase 3 trial assessing the efficacy and safety of grass allergy immunotherapy tablet in subjects with grass pollen-induced allergic rhinitis with or without conjunctivitis, with or without asthma

Table 3 **DSS, DMS, RQLQ(S) scores* and percent well days during the grass pollen season**

	Placebo (n = 166)	Grass AIT (n = 163)	Difference	95% CI for difference	P value
DSS, mean (SE)	6.06 (.40)	5.69 (.39)	-0.37	[-0.41; 1.16]	0.3475
DMS, mean (SE)	1.47 (.22)	1.07 (.20)	-0.40	[-0.05; 0.85]	0.0827
RQLQ(S)† score, mean (SE)	1.44 (.12)	1.36 (.12)	-0.08	[-0.16; 0.32]	0.5293
Percent well days, mean (SE)	26.03 (3.13)	27.44 (3.29)	1.42	[-8.56; 5.73]	0.6965

*Scores were adjusted using the analysis of variance (ANOVA) model, with treatment group as fixed effect and pollen region as random effect. †RQLQ(S): number of observations: placebo = 840, Grass AIT = 801. AIT Allergy immunotherapy tablet, CI Confidence interval, DMS Daily medication score, DSS Daily symptom score, RQLQ(S) Rhinoconjunctivitis quality of life questionnaire with standardized activities, SE Standard error.

ISSN: 1477-5751